Acalabrutinib is a Bruton tyrosine kinase (BTK) inhibitor, and preclinical studies have suggested that combining BTK inhibition with a PD-1 blockade may enhance anti-tumor activity in PDAC. The gene discussed is PDCD1; the disease is neoplasm.